| Literature DB >> 26751473 |
Marlène Perignon1, Marion Fiorentino2, Khov Kuong3,4, Marjoleine A Dijkhuizen5, Kurt Burja6, Megan Parker7, Chhoun Chamnan8, Jacques Berger9, Frank T Wieringa10.
Abstract
In Cambodia, micronutrient deficiencies remain a critical public health problem. Our objective was to evaluate the impact of multi-micronutrient fortified rice (MMFR) formulations, distributed through a World Food Program school-meals program (WFP-SMP), on the hemoglobin concentrations and iron and vitamin A (VA) status of Cambodian schoolchildren. The FORISCA-UltraRice+NutriRice study was a double-blind, cluster-randomized, placebo-controlled trial. Sixteen schools participating in WFP-SMP were randomly assigned to receive extrusion-fortified rice (UltraRice Original, UltraRice New (URN), or NutriRice) or unfortified rice (placebo) six days a week for six months. Four additional schools not participating in WFP-SMP were randomly selected as controls. A total of 2440 schoolchildren (6-16 years old) participated in the biochemical study. Hemoglobin, iron status, estimated using inflammation-adjusted ferritin and transferrin receptors concentrations, and VA status, assessed using inflammation-adjusted retinol-binding protein concentration, were measured at the baseline, as well as at three and six months. Baseline prevalence of anemia, depleted iron stores, tissue iron deficiency, marginal VA status and VA deficiency were 15.6%, 1.4%, 51.0%, 7.9%, and 0.7%, respectively. The strongest risk factors for anemia were hemoglobinopathy, VA deficiency, and depleted iron stores (all p < 0.01). After six months, children receiving NutriRice and URN had 4 and 5 times less risk of low VA status, respectively, in comparison to the placebo group. Hemoglobin significantly increased (+0.8 g/L) after three months for the URN group in comparison to the placebo group; however, this difference was no longer significant after six months, except for children without inflammation. MMFR containing VA effectively improved the VA status of schoolchildren. The impact on hemoglobin and iron status was limited, partly by sub-clinical inflammation. MMFR combined with non-nutritional approaches addressing anemia and inflammation should be further investigated.Entities:
Keywords: Cambodia; anemia; iron; malnutrition; micronutrient deficiencies; micronutrient status; nutrition intervention; rice fortification; schoolchildren; vitamin A
Mesh:
Substances:
Year: 2016 PMID: 26751473 PMCID: PMC4728643 DOI: 10.3390/nu8010029
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Trial profile. THR: take-home ration, URO: UltraRice original formulation, URN: UltraRice new formulation, WFP-SMP: World Food Program school-meal program.
Micronutrient contents of the fortified rices per 100 g of uncooked blended rice.
| Micronutrients | URO | URN | NutriRice |
|---|---|---|---|
| Iron (mg) | 10.67 | 7.55 | 7.46 |
| Zinc (mg) | 3.04 | 2.02 | 3.68 |
| Vitamin B1 (mg) | 1.06 | 1.43 | 0.69 |
| Folic acid (mg) | 0.17 | 0.28 | 0.14 |
| Vitamin A (IU) | - | 2140 | 960 |
| Vitamin B3 (mg) | - | 12.57 | 7.98 |
| Vitamin B12 (μg) | - | 3.8 | 1.26 |
| Vitamin B6 (mg) | - | - | 0.92 |
URO: UltraRice original formulation, URN: UltraRice new formulation.
Baseline characteristics of all children participating in the study and for each intervention group.
| OUTCOMES | ALL | CONTROL | PLACEBO | URO | URN | NUTRIRICE | |
|---|---|---|---|---|---|---|---|
| N | 2440 | 490 | 479 | 476 | 496 | 499 | |
| Age (year) | 9.65 ± 2.26 | 9.82 ± 2.30 | 9.61 ± 2.28 | 9.55 ± 2.14 | 9.64 ± 2.22 | 9.60 ± 2.35 | NS |
| % girls | 49.9 ( | 50.6 ( | 49.9 ( | 49.6 ( | 50.6 ( | 48.9 ( | NS |
| % inflammation | 39.5 ( | 45.6 a ( | 43.5 a ( | 42.3 a,b ( | 32.3 c ( | 34.0 b,c ( | <0.05 |
| % parasite infection | 17.9 ( | 9.4 a ( | 22.9 b ( | 23.9 b ( | 19.5 b,c ( | 12.9 a,c ( | <0.05 |
| Hb E ≤ 5% | 54.1 ( | 57.4 a,b ( | 60.1 b ( | 52.7 a,b ( | 50.7 a,b ( | 49.5 a ( | <0.05 |
| Hb E 5%–80% | 37.8 ( | 36.0 a,b ( | 31.7 b ( | 41.2 a ( | 39.5 a,b ( | 40.6 a,b ( | <0.05 |
| HbE > 80% | 8.1 ( | 6.6 ( | 8.2 ( | 6.1 ( | 9.8 ( | 9.9 ( | NS |
| Hb (g/L) | 124.2 ± 0.2 | 125.6 ± 0.4 a | 123.6 ± 0.4 b | 124.3 ± 0.4 a,b | 123.6 ± 0.4 b | 124.1 ± 0.4 a,b | <0.05 |
| % anemia | 15.6 ( | 9.8 a ( | 18.9 b ( | 15.3 a,b ( | 17.8 b ( | 16.4 b ( | <0.05 |
| FER 1 (μg/L) | 76.2 ± 36.9 ( | 83.0 ± 35.8 a ( | 77.0 ± 36.5 a,b ( | 79.7 ±38.8 a ( | 69.7 ± 36.3 c ( | 71.9 ± 35.3 b,c ( | <0.05 |
| % FER 1 < 15 μg/L | 1.4 ( | 0.2 a ( | 0.4 a ( | 0.9 a ( | 3.7 b ( | 1.9 a,b ( | <0.05 |
| TFR (mg/L) | 8.8 ± 2.5 ( | 8.5 ± 2.1 a ( | 9.0 ± 2.4 b ( | 9.1 ± 2.5 b ( | 8.4 ± 2.5 a ( | 8.9 ± 3.0 a,b ( | <0.05 |
| % TFR > 8.3 mg/L | 51.0 ( | 46.7 a ( | 55.6 a,b ( | 56.6 b ( | 47.0 a ( | 49.2 a,b ( | <0.05 |
| % ID 2 total | 51.2 ( | 46.7 a ( | 55.6 a,b ( | 56.6 b ( | 47.6 a,b ( | 49.6 a,b ( | <0.05 |
| % ID 2 with anemia | 9.9 ( | 6.4 a ( | 12.1 b ( | 10.4 a,b ( | 10.6 a,b ( | 10.1 a,b ( | <0.05 |
| Body iron (mg/kg) | 6.0 ± 2.2 ( | 6.5 ± 1.8 a ( | 6.0 ± 2.0 b ( | 6.0 ± 2.2 b ( | 5.8 ± 2.4 b ( | 5.8 ± 2.4 b ( | <0.05 |
| % BI ≥ 4 mg/kg | 86.2 ( | 92.6% a ( | 87.2 a,b ( | 86.2 b ( | 83.8 b ( | 81.5 b ( | <0.05 |
| % BI 0–4 mg/kg | 11.9 ( | 6.8% a ( | 11.7 a,b ( | 12.6 b ( | 12.7 b ( | 15.5 b ( | <0.05 |
| % BI < 0 mg/kg | 1.9 ( | 0.6 a ( | 1.1 a,b ( | 1.3 a,b ( | 3.5 b ( | 2.9 a,b ( | <0.05 |
| RBP 1 (μmol/L) | 1.58 ± 0.43 ( | 1.60 ± 0.39 a,d ( | 1.62 ± 0.43 a,
b ( | 1.69 ± 0.43 b ( | 1.48 ± 0.43 c ( | 1.52 ± 0.44 c,d ( | <0.05 |
| % marginal VA status 3 | 7.9 ( | 5.3 a ( | 6.9 a,b ( | 3.2 a ( | 12.9 c ( | 11.1 b,c ( | <0.05 |
| % VAD 4 | 0.7 ( | 0.2 ( | 0.4 ( | 0.2 ( | 1.2 ( | 1.5 ( | |
Results are mean ± SD unless stated, 1 corrected for inflammation using multiplier correction factors published by Thurnham et al. [19,24]; 2 based on FER 1 < 15 μg/L and/or TfR > 8.3 mg/L; 3 0.7 ≤ RBP 1< 1.05 μmol/L; 4 RBP 1< 0.7 μmol/L; 5 from ANOVA test. Groups in the same subset (a, b, or c) do not differ significantly from each other’s at the 0.05 level (Bonferroni post hoc test). BI: body iron, Hb: hemoglobin, FER: ferritin, TfR: transferrin receptors, ID: iron-deficiency, NS: not significant, URO: UltraRice original formula, URN: UltraRice new formula, RBP: retinol binding protein, VA: vitamin A, VAD: vitamin A deficiency.
Risk factors for anemia at baseline.
| Factors | Adjusted OR 2 (95% CI) | |
|---|---|---|
| 0.86 (0.62; 1.19) | 0.355 | |
| 1.03 (0.96; 1.12) | 0.378 | |
| 1.63 (1.10; 2.42) | 0.016 | |
| Incubation | 1.95 (0.26; 14.58) | 0.514 |
| Early convalescence | 2.20 (1.08; 4.48) | 0.029 |
| Late convalescence | 1.18 (0.82; 1.69) | 0.375 |
| 5% ≤ HbE < 80% | 1.87 (1.30; 2.69) | 0.001 |
| HbE ≥ 80% | 24.10 (15.09; 38.49) | <0.001 |
| marginal VA status (0.7 < RBP 1 < 1.05 μmol/L) | 1.57 (0.91; 2.72) | 0.106 |
| VAD (RBP 1 < 0.7 μmol/L) | 8.56 (2.30; 31.89) | 0.001 |
| 52.97 (11.43; 245.55) | <0.001 | |
| 0.99 (0.70; 1.42) | 0.979 |
1 corrected for inflammation; 2 from binary logistic regression, adjusted for age, gender, parasite infection, inflammation, hemoglobinopathy, VA and iron status. Hb: hemoglobin, FER: ferritin, TfR: transferrin receptors, VA: vitamin A, VAD: vitamin A deficiency.
Biochemical outcomes and effect sizes after three and six months of intervention for all participating children.
| B | Placebo | 470 | 123.7 | 1.3 | - | 462 | 77.5 | 3.5 | - | ||
| URO | 471 | 124.7 | 1.3 | - | 470 | 79.9 | 3.5 | - | |||
| URN | 494 | 123.7 | 1.3 | - | 489 | 70.0 | 3.5 | - | |||
| Nutririce | 482 | 124.4 | 1.3 | - | 476 | 72.1 | 3.5 | - | |||
| M | Placebo | 428 | 123.3 | 1.3 | - | 426 | 69.0 | 3.5 | - | ||
| URO | 428 | 123.5 | 1.3 | −0.74 (−1.54; 0.06) | 0.068 | 428 | 68.4 | 3.6 | −3.08 (−7.22; 1.06) | 0.144 | |
| URN | 434 | 124.1 | 1.3 | 0.80 (0.01; 1.59) | 0.048 | 347 | 64.2 | 3.6 | 2.72 (−1.57; 7.02) | 0.214 | |
| Nutririce | 394 | 124.4 | 1.3 | 0.50 (−0.31; 1.31) | 0.230 | 393 | 66.5 | 3.6 | 2.88 (−1.33; 7.09) | 0.180 | |
| E | Placebo | 425 | 122.6 | 1.3 | - | 421 | 71.6 | 3.6 | - | ||
| URO | 445 | 124.1 | 1.3 | 0.51 (−0.28; 1.30) | 0.207 | 443 | 72.6 | 3.5 | −1.46 (−5.58; 2.65) | 0.486 | |
| URN | 464 | 123.0 | 1.3 | 0.36 (−0.42; 1.14) | 0.368 | 463 | 74.8 | 3.5 | 10.70 (6.62; 14.78) | <0.001 | |
| Nutririce | 454 | 123.5 | 1.3 | 0.19 (−0.60; 0.98) | 0.633 | 450 | 74.5 | 3.5 | 8.32 (4.19; 12.44) | <0.001 | |
| B | Placebo | 462 | 8.98 | 0.24 | - | 462 | 6.01 | 0.27 | - | ||
| URO | 470 | 9.11 | 0.24 | - | 470 | 6.05 | 0.27 | - | |||
| URN | 489 | 8.42 | 0.24 | - | 489 | 5.79 | 0.27 | - | |||
| Nutririce | 476 | 8.87 | 0.24 | - | 476 | 5.78 | 0.27 | - | |||
| M | Placebo | 426 | 8.11 | 0.24 | - | 426 | 5.99 | 0.27 | - | ||
| URO | 428 | 7.98 | 0.24 | −0.26 (−0.53; 0.01) | 0.059 | 428 | 5.94 | 0.27 | −0.09 (−0.30; 0.13) | 0.427 | |
| URN | 347 | 7.90 | 0.24 | 0.34 (0.06; 0.62) | 0.017 | 347 | 5.75 | 0.27 | −0.01 (−0.23; 0.21) | 0.928 | |
| Nutririce | 393 | 8.49 | 0.24 | 0.49 (0.21; 0.76) | 0.001 | 393 | 5.62 | 0.27 | −0.13 (−0.35; 0.08) | 0.227 | |
| E | Placebo | 421 | 8.18 | 0.24 | - | 421 | 6.11 | 0.27 | - | ||
| URO | 443 | 8.08 | 0.24 | −0.24 (−0.50; 0.04) | 0.088 | 443 | 6.09 | 0.27 | −0.06 (−0.27; 0.15) | 0.582 | |
| URN | 463 | 8.51 | 0.24 | 0.89 (0.62; 1.15) | <0.001 | 463 | 6.00 | 0.27 | 0.11 (−0.09; 0.32) | 0.284 | |
| Nutririce | 450 | 8.74 | 0.24 | 0.66 (0.39; 0.93) | <0.001 | 450 | 5.87 | 0.27 | −0.01 (−0.22; 0.20) | 0.947 | |
Results are mean ± SE unless stated, 1 corrected for inflammation; 2 Generalized linear mixed models adjusted for age, gender and baseline characteristics were used to evaluate the effects of time × group interaction term, B: baseline, M: midline, E: endline, Hb: hemoglobin, FER: ferritin, TfR: transferrin receptors, URO: UltraRice original formula, URN: UltraRice new formula.
Biochemical outcomes and effect sizes after three and six months of intervention for the sub-sample of children with no inflammation at baseline, midline, and endline.
| Time Point | Group | Hb (g/L) | FER 1 (μg/L) | TFR (mg/L) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SE | Interaction Term 2 | Mean | SE | Interaction Term 2 | Mean | SE | Interaction Term 2 | ||||||||
| β Coefficient (95% CI) | β Coefficient (95% CI) | β Coefficient (95% CI) | ||||||||||||||
| B | Placebo | 125 | 124.7 | 1.6 | - | 125 | 84.5 | 5.0 | - | 125 | 8.3 | 0.3 | - | |||
| URO | 142 | 125.3 | 1.6 | - | 142 | 81.8 | 4.8 | - | 142 | 8.9 | 0.3 | - | ||||
| URN | 136 | 124.7 | 1.7 | - | 136 | 68.5 | 5.0 | - | 136 | 7.9 | 0.3 | - | ||||
| Nutririce | 125 | 124.8 | 1.6 | - | 125 | 71.6 | 4.9 | - | 125 | 8.3 | 0.3 | - | ||||
| M | Placebo | 125 | 123.9 | 1.6 | - | 125 | 78.0 | 5.0 | - | 125 | 7.8 | 0.3 | - | |||
| URO | 142 | 124.2 | 1.6 | –0.3 (–1.7; 1.1) | 0.688 | 142 | 73.1 | 4.8 | –2.2 (–9.3; 5.0) | 0.550 | 142 | 7.8 | 0.3 | –0.6 (–1.1; –0.2) | 0.004 | |
| URN | 135 | 126.0 | 1.7 | 2.1 (0.7; 3.5) | 0.004 | 136 | 63.0 | 5.0 | 1.0 (–6.2; 8.3) | 0.781 | 136 | 7.5 | 0.3 | 0.1 (–0.4; 0.5) | 0.747 | |
| Nutririce | 125 | 125.1 | 1.6 | 1.1 (–0.4; 2.5) | 0.147 | 125 | 66.6 | 4.9 | 1.6 (–5.8; 9.0) | 0.669 | 125 | 7.8 | 0.3 | 0.0 (–0.4; 0.5) | 0.936 | |
| E | Placebo | 125 | 123.0 | 1.6 | - | 125 | 79.2 | 5.0 | - | 125 | 7.5 | 0.3 | - | |||
| URO | 142 | 124.9 | 1.6 | 1.4 (–0.0; 2.8) | 0.054 | 142 | 77.9 | 4.8 | 1.4 (–5.7; 8.6) | 0.697 | 142 | 8.0 | 0.3 | –0.1 (–0.5; 0.3) | 0.646 | |
| URN | 136 | 124.7 | 1.7 | 1.8 (0.3; 3.2) | 0.015 | 136 | 75.9 | 5.0 | 12.7 (5.5; 20.0) | 0.001 | 136 | 8.2 | 0.3 | 1.1 (0.6; 1.5) | <0.001 | |
| Nutririce | 125 | 124.3 | 1.6 | 1.2 (–0.2; 2.7) | 0.095 | 125 | 73.1 | 4.9 | 6.8 (–0.5; 14.2) | 0.070 | 125 | 8.2 | 0.3 | 0.7 (0.3; 1.2) | 0.001 | |
Results are mean ± SE unless stated, 1 corrected for inflammation; 2 Generalized linear mixed models adjusted for age, gender and baseline characteristics were used to evaluate the effects of time × group interaction term, B: baseline, M: midline, E: endline, Hb: hemoglobin, FER: ferritin, TfR: transferrin receptors, URO: UltraRice original formula, URN: UltraRice new formula.
Prevalence of marginal VA status after three and six months of intervention among all children.
| All Children | |||||
|---|---|---|---|---|---|
| Time Point | Group | % (95% CI) | Interaction Term | ||
| Adjusted OR 1 (95% CI) | |||||
| B | Placebo | 462 | 5.4 (2.9; 9.9) | - | |
| URO | 470 | 2.6 (1.3; 5.4) | - | ||
| URN | 489 | 12.3 (7.2; 20.3) | - | ||
| Nutririce | 476 | 11.0 (6.4; 18.4) | - | ||
| M | Placebo | 426 | 11.0 (6.3; 18.6) | - | |
| URO | 428 | 13.0 (7.6; 21.4) | 2.55 (1.22; 5.33) | 0.012 | |
| URN | 347 | 15.4 (9.0; 25.1) | 0.60 (0.33; 1.10) | 0.101 | |
| Nutririce | 393 | 12.2 (7.0; 20.4) | 0.52 (0.28; 0.96) | 0.036 | |
| E | Placebo | 421 | 12.4 (7.1; 20.6) | - | |
| URO | 443 | 8.3 (4.7; 14.5) | 1.37 (0.65; 2.91) | 0.410 | |
| URN | 463 | 6.3 (3.4; 11.4) | 0.20 (0.10; 0.37) | <0.001 | |
| Nutririce | 450 | 6.8 (3.7; 12.1) | 0.24 (0.13; 0.45) | <0.001 | |
1 mixed logistic regression model adjusted for age, gender and baseline characteristics was used to evaluate the effect of time × group interaction term. B: baseline, M: midline, E: endline, URO: UltraRice original formula, URN: UltraRice new formula.